Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.

NCT03343704 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03343704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2018
Completion date
July 2, 2020
Enrollment
19 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhage